On Aug. 5, 2024, Novartis and Viatris were named a federal lawsuit in Maryland by the family of…
On Aug. 24, 2023, researchers at City of Hope announced were awarded $32.3 million from the California Institute…
On Aug. 1, 2023, more than 70 years after doctors at Johns Hopkins Hospital took Henrietta Lacks’ cervical…
On Mar. 7, 2023, researchers at the National Institutes of Health reported the benefits of screening adult patients…
On Feb. 15, 2023, it was reported that a 53-year-old man in Germany had become at least the…
On Jul. 27, 2022, City of Hope announced that a 66-year-old man who was diagnosed with HIV in…
On Feb. 15, 2022, a woman with HIV who received a cord blood stem cell transplant to treat…
On Feb. 2, 2022, a new analysis of the first two patients treated in a clinical trial with…
On Oct. 13, 2021, the World Health Organization (WHO) honoured the late Henrietta Lacks with a WHO Director-General’s…
On Oct. 1, 2021, Kite, a Gilead Company, announced the U.S. Food and Drug Administration had granted approval…
On Apr. 21, 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson announced U.S. Food and Drug Administration…
On Sept. 12, 2019, UPenn completed its exclusive, 7-year research and development alliance with Novartis, that spawned the…
On Aug. 21, 2019, the Siteman Cancer Center announced it was awarded a $15 million grant to better…
On Jan. 29, 2019, Ontario Institute for Cancer Research’s (OICR) Drug Discovery Program’s first-of-its-kind leukemia therapy discovery received…
On Nov. 28, 2018, The U.S. Food and Drug Administration (FDA) announced it had approved the first ever…
On Mar. 9, 2018, Boston-based cancer company Partner Therapeutics announced that it had acquired the global rights to…
On Aug. 30, 2017, the U.S. Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) for certain pediatric and…
On Dec. 1, 2013, researchers at the Princess Margaret Hospital in Toronto, led by Dr. John Dick, announced…
On Jan. 31, 2012, the U.S. Food and Drug Administration (FDA) granted Gleevec (imatinib) regular approval for use…
On Feb. 22, 2011, Foster City, Calif-based Gilead Sciences and Calistoga Pharmaceuticals announced Gilead’s acquisition of Calistoga for…
On Nov. 5, 2008, Siteman Cancer Center and The Genome Center researchers Timothy J. Ley, MD, Elaine Mardis,…
On Jan. 23, 2007, results from a large phase III clinical trial show that adult patients with previously…
On Oct. 19, 2006, the U.S. Food and Drug Administration (FDA) approved the drug, Gleevec developed by Oregon…
In 2006, Calistoga Pharmaceuticals was founded as a Seattle-based spin-off from ICOS Corp. that was dedicated to developing…
On Nov. 7, 2001, the Oregon Health Sciences University Foundation (OHSU) announced that the Klamath Falls-based JELD-WEN Foundation…
On May 10, 2001, the U.S. Food and Drug Administration (FDA) approved Gleevec, the world’s first targeted cancer…
In 2001, the drug imatinib mesylate (Gleevec) was shown in a clinical trial to be effective against chronic…
In 2000, researchers from Lawrence Berkeley, Lawrence Livermore, and Los Alamos national laboratories at the Joint Genome Institute…
In 1997, a mouse model of promyelocytic leukemia was developed by Washington University – St. Louis researcher Timothy…
In 1997, the National Cancer Institute (NCI) and Chinese scientists found that occupational exposure to benzene is associated…